Reaction
Nephrosclerosis reporting signals
As of the last recalculation, Nephrosclerosis appears in 1,106 FAERS reports alongside 20 co-occurring drug terms. The strongest observed disproportionality signal is BASILIXIMAB (PRR 42.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Basiliximab | 26 | 42.6 | 42.7 |
| Lansoprazole | 284 | 40.0 | 40.1 |
| Esomeprazole | 90 | 29.6 | 29.7 |
| Esomeprazole Magnesium | 195 | 18.8 | 18.8 |
| Epoetin Alfa | 11 | 17.6 | 17.7 |
| Esomeprazole Magnesium Capsule, Delayed Release | 13 | 17.0 | 17.1 |
| Esomeprazole Magnesium Delayed Release Capsules | 13 | 17.0 | 17.1 |
| Esomeprazole Magnesium Dihydrate | 13 | 17.0 | 17.0 |
| Metolazone | 8 | 13.5 | 13.5 |
| Labetalol | 9 | 12.8 | 12.8 |
| Quinapril Hydrochloride | 5 | 12.0 | 12.0 |
| Eplerenone | 8 | 11.8 | 11.8 |
| Pemetrexed | 12 | 10.6 | 10.6 |
| Dexlansoprazole | 22 | 10.1 | 10.1 |
| Pemetrexed Disodium | 14 | 7.0 | 7.0 |
| Paricalcitol | 5 | 6.7 | 6.7 |
| Pseudoephedrine Hcl | 3 | 5.1 | 5.1 |
| Methoxy Polyethylene Glycol-Epoetin Beta | 3 | 5.1 | 5.1 |
| Orlistat | 7 | 5.1 | 5.1 |
| Oxymorphone Hydrochloride | 3 | 4.9 | 4.9 |